紫杉醇药物涂层球囊治疗股腘动脉闭塞性动脉硬化的疗效及安全性  

Efficacy and safety of paclitaxel drug-coated balloon in the treatment of femoropopliteal arteriosclerosis obliterans

作　　者：金翻亮 任补元 贺彦龙 Jin Fanliang;Ren Buyuan;He Yanlong(Department of Vascular Surgery,Inner Mongolia People's Hospital,Hohhot 010017,Inner Mongolia,China)

机构地区：[1]内蒙古自治区人民医院血管外科,内蒙古呼和浩特010017

出　　处：《血管与腔内血管外科杂志》2022年第3期284-287,共4页Journal of Vascular and Endovascular Surgery

基　　金：内蒙古自治区自然科学基金面上项目(2013MS)。

摘　　要：目的观察紫杉醇药物涂层球囊(DCB)治疗股腘动脉闭塞性动脉硬化的疗效及安全性。方法收集2018年1月至2020年2月内蒙古自治区人民医院收治的86例股腘动脉闭塞性动脉硬化患者。按照治疗方法的不同将其分为研究组(n=43,予以紫杉醇DCB治疗)和对照组(n=43,予以普通球囊治疗)。术前、术后6个月,比较两组患者Rutherford分级、踝肱指数(ABI)、靶病变最小管腔直径(MLD)、晚期管腔丢失(LLL)、不良事件发生率。结果术后6个月,研究组患者ABI高于对照组患者,MLD宽于对照组患者,LLL少于对照组患者,Rutherford分级优于对照组患者;研究组患者不良事件总发生率为13.95%(6/43),低于对照组患者的34.88%(15/43),差异均有统计学意义(P<0.05)。结论股腘动脉闭塞性动脉硬化患者行紫杉醇DCB疗法可以获得良好的疗效,术后不良事件发生率较低,值得临床推广使用。Objective To observe the efficacy and safety of paclitaxel drug-coated balloon(DCB)in the treatment of femoropopliteal arteriosclerosis obliterans.Method A total of 86 patients with femoropopliteal arteriosclerosis obliterans admitted to the Inner Mongolia People's Hospital from January 2018 to February 2020 were collected.They were divided into a study group(n=43,treated with paclitaxel DCB)and a control group(n=43,treated with ordinary balloon)according to the different treatment methods.Before the operation and 6 months after the operation,Rutherford grade,ankle-brachial index(ABI),minimum lumen diameter(MLD),late lumen loss(LLL),and incidence of adverse events were compared between the two groups.Result Six months after the operation,the ABI of the study group was higher than that of the control group,the MLD was wider than that of the control group,and the LLL was less than that of the control group;the Rutherford grade of the patients in the study group was better than that of the patients in the control group;the total incidence of adverse events in the study group was 13.95%(6/43),which was lower than 34.88%(15/43)in the control group,the differences were statistically significant(P<0.05).Conclusion Paclitaxel DCB therapy in patients with femoropopliteal arteriosclerosis obliterans can obtain good curative effect,and the incidence of postoperative adverse events is low,which is worthy of clinical promotion.

关 键 词：踝肱指数 闭塞性动脉硬化 药物涂层球囊 

分 类 号：R543[医药卫生—心血管疾病]